Horm Metab Res 2006; 38(11): 761-766
DOI: 10.1055/s-2006-955089
Original Clinical

© Georg Thieme Verlag KG Stuttgart · New York

Arabinoxylan Fibre Consumption Improved Glucose Metabolism, but did not Affect Serum Adipokines in Subjects with Impaired Glucose Tolerance

A. L. Garcia 1 , J. Steiniger 1 , S. C. Reich 1 , M. O. Weickert 2 , I. Harsch 3 , A. Machowetz 1 , M. Mohlig 2 , J. Spranger 2 , N. N. Rudovich 2 , F. Meuser 4 , J. Doerfer 4 , N. Katz 5 , M. Speth 5 , H. J. F. Zunft 1 , 6 , A. H. F. Pfeiffer 2 , C. Koebnick 1 , 7
  • 1Dietary Fibre and the Metabolic Syndrome Group, German Institute of Human Nutrition, Potsdam-Rehbruecke, Nuthetal, Germany
  • 2Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany
  • 3Medical Department I, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany
  • 4Institute of Food Technology and Food Chemistry, Technical University Berlin, Berlin, Germany
  • 5Department of Clinical Chemistry, University of Giessen, Giessen, Germany
  • 6Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany
  • 7Department of Preventive Medicine, University of Southern California, USA
Further Information

Publication History

Received 16 February 2006

Accepted after second revision 13 June 2006

Publication Date:
16 November 2006 (online)

Abstract

The consumption of arabinoxylan, a soluble fibre fraction, has been shown to improve glycemic control in type 2 diabetic subjects. Soluble dietary fibre may modulate gastrointestinal or adipose tissue hormones regulating food intake. The present study investigated the effects of arabinoxylan consumption on serum glucose, insulin, lipids, leptin, adiponectin and resistin in subjects with impaired glucose tolerance. In a randomized, single-blind, controlled, crossover intervention trial, 11 adults consumed white bread rolls as either placebo or supplemented with 15 g arabinoxylan for 6 weeks with a 6-week washout period. Fasting serum glucose, insulin, triglycerides, unesterified fatty acids, apolipoprotein A1 and B, adiponectin, resistin and leptin were assessed before and after intervention. Fasting serum glucose, serum triglycerides and apolipoprotein A-1 were significantly lower during arabinoxylan consumption compared to placebo (p=0.029, p=0.047; p=0.029, respectively). No effects of arabinoxylan were observed for insulin, adiponectin, leptin and resistin as well as for apolipoprotein B, and unesterified fatty acids. In conclusion, the consumption of AX in subjects with impaired glucose tolerance improved fasting serum glucose, and triglycerides. However, this beneficial effect was not accompanied by changes in fasting adipokine concentrations.

References

  • 1 Brennan CS. Dietary fibre, glycaemic response, and diabetes.  Mol Nutr Food Res. 2005;  49 560-570
  • 2 Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fibre: a meta-analysis.  Am J Clin Nutr. 1999;  69 30-42
  • 3 Anderson JW, Davidson MH, Blonde L, Brown WV, Howard WJ, Ginsberg H, Allgood LD, Weingand KW. Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia.  Am J Clin Nutr. 2000;  71 1433-1438
  • 4 Onning G, Wallmark A, Persson M, Akesson B, Elmstahl S, Oste R. Consumption of oat milk for 5 weeks lowers serum cholesterol and LDL cholesterol in free-living men with moderate hypercholesterolemia.  Ann Nutr Metab. 1999;  43 301-309
  • 5 Slavin JL. Dietary fibre and body weight.  Nutrition. 2005;  21 411-418
  • 6 Charalampopoulos D, Wang R, Pandiella SS, Webb C. Application of cereals and cereal components in functional foods: a review.  Int J Food Microbiol. 2002;  79 131-141
  • 7 Lu ZX, Walker KZ, Muir JG, Mascara T, O'Dea K. Arabinoxylan fibre, a byproduct of wheat flour processing, reduces the postprandial glucose response in normoglycemic subjects.  Am J Clin Nutr. 2000;  71 1123-1128
  • 8 Lu ZX, Walker KZ, Muir JG, O'Dea K. Arabinoxylan fibre improves metabolic control in people with Type II diabetes.  Eur J Clin Nutr. 2004;  58 621-628
  • 9 Lu ZX, Walker KZ, Muir JG, Mascara T, O'Dea K. Arabinoxylan fibre, a byproduct of wheat flour processing, reduces the postprandial glucose response in normoglycemic subjects.  Am J Clin Nutr. 2000;  71 1123-1128
  • 10 Mohlig M, Koebnick C, Weickert MO, Lueder W, Otto B, Steiniger J, Twilfert M, Meuser F, Pfeiffer AF, Zunft HJ. Arabinoxylan-enriched meal increases serum ghrelin levels in healthy humans.  Horm Metab Res. 2005;  37 303-308
  • 11 Hallfrisch J, Facn, Behall KM. Mechanisms of the effects of grains on insulin and glucose responses.  J Am Coll Nutr. 2000;  19 320S-325S
  • 12 Jenkins DJ, Wolever TM, Leeds AR, Gassull MA, Haisman P, Dilawari J, Goff DV, Metz GL, Alberti KG. Dietary fibres, fibre analogues, and glucose tolerance: importance of viscosity.  Br Med J. 1978;  1 1392-1394
  • 13 Song YJ, Sawamura M, Ikeda K, Igawa S, Yamori Y. Soluble dietary fibre improves insulin sensitivity by increasing muscle GLUT-4 content in stroke-prone spontaneously hypertensive rats.  Clin Exp Pharmacol Physiol. 2000;  27 41-45
  • 14 Sparti A, Milon H, Di Vetta V, Schneiter P, Tappy L, Jequier E, Schutz Y. Effect of diets high or low in unavailable and slowly digestible carbohydrates on the pattern of 24-h substrate oxidation and feelings of hunger in humans.  Am J Clin Nutr. 2000;  72 1461-1468
  • 15 Bourdon I, Yokoyama W, Davis P, Hudson C, Backus R, Richter D, Knuckles B, Schneeman BO. Postprandial lipid, glucose, insulin, and cholecystokinin responses in men fed barley pasta enriched with beta-glucan.  Am J Clin Nutr. 1999;  69 55-63
  • 16 Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, Horvath TL, Cone RD, Low MJ. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus.  Nature. 2001;  411 480-484
  • 17 Fischer S, Hanefeld M, Haffner SM, Fusch C, Schwanebeck U, Kohler C, Fucker K, Julius U. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass.  Acta Diabetol. 2002;  39 105-110
  • 18 Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.  J Clin Endocrinol Metab. 2001;  86 1930-1935
  • 19 Stefan N, Stumvoll M. Adiponectin-its role in metabolism and beyond.  Horm Metab Res. 2002;  34 469-474
  • 20 Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Adiponectin and protection against type 2 diabetes mellitus.  Lancet. 2003;  361 226-228
  • 21 Mohlig M, Wegewitz U, Osterhoff M, Isken F, Ristow M, Pfeiffer AF, Spranger J. Insulin decreases human adiponectin plasma levels.  Horm Metab Res. 2002;  34 655-658
  • 22 Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes.  J Clin Endocrinol Metab. 2005;  90 4542-4548
  • 23 Herrmann BL, Berg C, Vogel E, Nowak T, Renzing-Koehler K, Mann K, Saller B. Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome.  Horm Metab Res. 2004;  36 54-61
  • 24 Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans.  Circulation. 2005;  111 932-939
  • 25 Schaffler A, Buchler C, Muller-Ladner U, Herfarth H, Ehling A, Paul G, Scholmerich J, Zietz B. Identification of variables influencing resistin serum levels in patients with type 1 and type 2 diabetes mellitus.  Horm Metab Res. 2004;  36 702-707
  • 26 Iqbal N, Seshadri P, Stern L, Loh J, Kundu S, Jafar T, Samaha FF. Serum resistin is not associated with obesity or insulin resistance in humans.  Eur Rev Med Pharmacol Sci. 2005;  9 161-165
  • 27 Romon M, Lebel P, Velly C, Marecaux N, Fruchart JC, Dallongeville J. Leptin response to carbohydrate or fat meal and association with subsequent satiety and energy intake.  Am J Physiol. 1999;  277 E855-E861
  • 28 Poppitt SD, Leahy FE, Keogh GF, Wang Y, Mulvey TB, Stojkovic M, Chan YK, Choong YS, McArdle BH, Cooper GJ. Effect of high-fat meals and fatty acid saturation on postprandial levels of the hormones ghrelin and leptin in healthy men.  Eur J Clin Nutr. 2006;  60 77-84
  • 29 Groschl M, Knerr I, Topf HG, Schmid P, Rascher W, Rauh M. Endocrine responses to the oral ingestion of a physiological dose of essential amino acids in humans.  J Endocrinol. 2003;  179 237-244
  • 30 Heini AF, Lara-Castro C, Schneider H, Kirk KA, Considine RV, Weinsier RL. Effect of hydrolyzed guar fibre on fasting and postprandial satiety and satiety hormones: a double-blind, placebo-controlled trial during controlled weight loss.  Int J Obes Relat Metab Disord. 1998;  22 906-909
  • 31 Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans.  J Clin Endocrinol Metab. 2003;  88 1730-1736
  • 32 Anderlova K, Kremen J, Dolezalova R, Housova J, Haluzikova D, Kunesova M, Hakuzik M. The influence of very-low-calorie-diet on serum leptin, soluble leptin receptor, adiponectin and resistin levels in obese women.  Physiol Res. 2006;  55 277-283
  • 33 Qi L, Rimm E, Liu S, Rifai N, Hu FB. Dietary glycemic index, glycemic load, cereal fibre, and plasma adiponectin concentration in diabetic men.  Diabetes Care. 2005;  28 1022-1028
  • 34 Kabir M, Oppert JM, Vidal H, Bruzzo F, Fiquet C, Wursch P, Slama G, Rizkalla SW. Four-week low-glycemic index breakfast with a modest amount of soluble fibres in type 2 diabetic men.  Metabolism. 2002;  51 819-826
  • 35 Koebnick C, Wagner K, Thielecke F, Moeseneder J, Hoehne A, Franke A, Meyer H, Garcia AL, Trippo U, Zunft HJ. Validation of a simplified physical activity record by doubly labeled water technique.  Int J Obes Relat Metab Disord. 2005;  29 302-309
  • 36 Koebnick C, Wagner K, Thielecke F, Dieter G, Hohne A, Franke A, Garcia AL, Meyer H, Hoffmann I, Leitzmann P, Trippo U, Zunft HJ. An easy-to-use semiquantitative food record validated for energy intake by using doubly labelled water technique.  Eur J Clin Nutr. 2005;  59 989-995
  • 37 Weickert MO, Mohlig M, Koebnick C, Holst JJ, Namsolleck P, Ristow M, Osterhoff M, Rochlitz H, Rudovich N, Spranger J, Pfeiffer AF. Impact of cereal fibre on glucose-regulating factors.  Diabetologia. 2005;  48 2343-2353
  • 38 Ferris WF, Naran NH, Crowther NJ, Rheeder P, van der Merwe L, Chetty N. The relationship between insulin sensitivity and serum adiponectin levels in three population groups.  Horm Metab Res. 2005;  37 695-701
  • 39 Esposito K, Nappo F, Giugliano F, Di Palo C, Ciotola M, Barbieri M, Paolisso G, Giugliano D. Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus.  Am J Clin Nutr. 2003;  78 1135-1140
  • 40 Couillard C, Mauriege P, Prud'homme D, Nadeau A, Tremblay A, Bouchard C, Despres JP. Plasma leptin concentrations: gender differences and associations with metabolic risk factors for cardiovascular disease.  Diabetologia. 1997;  40 1178-1184
  • 41 Koebnick C, Wagner K, Garcia AL, Gruendel S, Lahmann PH, Weickert MO, Möhlig M, Harsch IA, Einig C, Speth M, Katz N, Trippo U, Zunft HJF. Increase in serum resistin during weight loss in overweight subjects is related to lipid metabolism.  Int J Obes Relat Metab Disord. 2006;  , in press
  • 42 Burnett MS, Lee CW, Kinnaird TD, Stabile E, Durrani S, Dullum MK, Devaney JM, Fishman C, Stamou S, Canos D, Zbinden S, Clavijo LC, Jang GJ, Andrews JA, Zhu J, Epstein SE. The potential role of resistin in atherogenesis.  Atherosclerosis. 2005;  182 241-248
  • 43 Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties.  J Immunol. 2005;  174 5789-5795
  • 44 Ballantyne CM, Nambi V. Apolipoprotein A-I and high-density lipoprotein: is this the beginning of the era of noninvasive angioplasty?.  J Am Coll Cardiol. 2004;  44 1436-1438
  • 45 Sniderman AD. How, when, and why to use apolipoprotein B in clinical practice.  Am J Cardiol. 2002;  90 48i-54i

Correspondence

Corinna KoebnickPh.D. 

Department of Preventive Medicine·University of Southern California

2250 Alcazar St

Room 210

Los Angeles

CA 90033

USA

Phone: 323/442/26 76

Fax: 323/442/41 03

Email: koebnick@usc.edu.de

    >